Some states cut GLP‑1 Medicaid

Some states are cutting Medicaid coverage for popular weight-loss drugs even as demand keeps climbing. (theguardian.com) KFF reported in January 2026 that 13 state Medicaid programs covered glucagon-like peptide-1 drugs for obesity treatment, down from 16 states in October 2025. California, Pennsylvania, New Hampshire and South Carolina were among the states that had ended or pulled back that coverage, while Michigan tightened eligibility. (kff.org) California’s state plan amendment, approved by the Centers for Medicare and Medicaid Services on March 12, 2026, updated Medi-Cal’s excluded drug list and took effect January 1, 2026. Pennsylvania won federal approval on March 4, 2026, for a change that updated “limitations to coverage of weight loss agents,” also effective January 1, 2026. (medicaid.gov 1) (medicaid.gov 2) The drugs at the center of the fight were first used to control blood sugar in type 2 diabetes, then became widely prescribed for obesity after studies showed larger weight loss than older medicines. KFF said Medicaid must cover these drugs for diabetes and some other approved uses, but states can choose whether to cover them when prescribed for weight loss alone. (kff.org) That distinction has become more important as the medicines picked up new medical uses. The Food and Drug Administration approved Wegovy in March 2024 to cut the risk of heart attack, stroke and cardiovascular death in some adults with cardiovascular disease and obesity or overweight, and approved Zepbound in December 2024 for obstructive sleep apnea in adults with obesity. (fda.gov 1) (fda.gov 2) KFF said gross Medicaid spending on selected glucagon-like peptide-1 drugs reached $4 billion in 2023, and states are reassessing coverage as budgets tighten. The group also said the 2025 reconciliation law’s Medicaid cuts added longer-term fiscal pressure on state programs. (kff.org 1) (kff.org 2) At the same time, Medicaid covers a population with high obesity rates. KFF said almost four in 10 adults and one quarter of children enrolled in Medicaid have obesity, which means coverage decisions affect millions of low-income patients. (kff.org) The Biden administration proposed in November 2024 to require Medicaid coverage of anti-obesity drugs and allow Medicare coverage, but KFF said the Trump administration later chose not to finalize that rule. Instead, federal officials have pursued other cost and access efforts while the basic Medicaid rule still leaves obesity-drug coverage optional for states. (kff.org) (kff.org) State officials have framed the rollbacks as budget control, but researchers told The Guardian the savings may be temporary if untreated obesity drives more diabetes, heart disease and other chronic illness later. For now, whether a low-income patient can get a drug such as Wegovy or Zepbound for obesity still depends heavily on which state they live in. (theguardian.com)